The US Food and Drug Administration plans to offer sponsors more guidance on clinical trial issues this year, including in the areas of pharmacogenomic data submission and use of digital health technologies.
The Center for Drug Evaluation and Research's 2020 guidance agenda of new and revised draft guidances it plans to...